Current Study Sample Clauses

Current Study. Building on past literature, the current study investigated if and how individual differences in vulnerable narcissism can influence the propensity to engage in the derogation of an innocent other following a self-esteem threat. The current study built on past work in important ways. First, it sought to clarify and extend our scientific understanding by directly investigating the role that vulnerable narcissism may play in predicting the use of other-derogation as a means of restoring self-esteem following a threat. Second, whereas prior work has largely examined how people respond to an “other” who is perceived to have provoked or otherwise wronged them (e.g., ▇▇▇▇▇, 2010), the current study examined whether this tendency to derogate extends to an “innocent other,” i.e,. someone who did not deliver the self-esteem threat. Lastly, the current research examined reactions to self-esteem threat in the context of a job evaluation and hiring process, thereby providing an important connection to real-world events.
View Source
Current Study. Given the heterogeneous natures of both psychopathy and depression and the complexities in the literature, I examined how psychopathic traits differentially relate with depressive features in two large community samples (n1=430; n2=441). The methodology adopted here affords several statistical advantages. First, as discussed earlier, clinical and forensic samples may be limited in their generalizability to more normative populations. By using a community population, the variability of the scores for both psychopathy and depression are potentially increased, thereby also increasing the generalizability of findings and statistical power for detecting meaningful effects. Relatedly, most evidence indicates that psychopathy and depression are continuous at a latent level (▇▇▇▇▇ et al., 2006; ▇▇▇▇▇▇ et al., 2005), allowing them to be profitably measured and studied in non-clinical populations. In addition, many studies have assessed psychopathy using only one measure, introducing mono-operation bias. I therefore used multiple measures of both psychopathy and depression to protect against mono-operation bias and build in conceptual (or “constructive,” see ▇▇▇▇▇▇, 1968) replication within samples. I also did not rely on total scores of psychopathy in my analyses, but instead analyzed how subdimensions of psychopathy related to features of depression.
View Source
Current Study. This study is part of a larger project. In the first part of the project we identified three reading profiles in 9-11-year-old children based on their online reading pro- cesses, think-aloud responses to text (▇▇▇▇▇▇▇▇ et al., 2018). In the current chapter, readers in the profiles Elaborating, Paraphrasing, and Literal Readers are com- pared on their ability to form a structured offline memory representation of narra- tive and expository texts, i.e. recalling information that is central to each text. Following prior research (▇▇▇▇▇▇▇▇ & ▇'▇▇▇▇▇, 1991; ▇▇▇▇▇▇ & ▇▇▇▇▇▇, 2009; 2011; ▇▇▇▇▇▇▇, 1982a, 1982b), we determined centrality of text units by im- portance ratings. We then examined the children’s recall of units rated as highly important and central to the text, and units rated as peripheral and less important. There are two research questions. First, do the children with different reading pro- files show similarities or differences regarding the centrality effect? We anticipate Elaborating Readers, who routinely use background knowledge and generate in- ferences, to show a larger centrality effect compared to Paraphrasing and Literal Readers. This would be reflected in a larger difference in their recall of central and peripheral text units. Furthermore, Paraphrasing Readers engage in more inference generation than Literal Readers and are expected to show a larger centrality effect than Literal Readers. Second, do any observed effects depend on text genre? Chil- dren in all profiles generated fewer inferences and showed an approach closer to the text for expository than for narrative texts (▇▇▇▇▇▇▇▇ et al., 2018). Therefore, it is possible that readers in all profiles show a larger centrality effect in their recall of narrative texts than of expository texts.
View Source
Current Study. The aims of the current study are 1) to determine whether previous findings from other CHR studies are replicated in the NAPLS CHR sample, 2) to test whether depression acts as mediator between sleep problem and positive prodromal symptoms in this CHR sample, 3) to test whether certain positive prodromal symptoms are more specifically associated with sleep problems than others, and 4) to explore whether sleep disturbance predicts subsequent worsening of prodromal psychotic symptoms and/or increased likelihood of later conversion to a psychotic illness. Based on previous research in CHR samples (i.e., ▇▇▇ et al., 2017; ▇▇▇▇▇▇▇▇-▇▇▇▇▇ et al., 2017), we hypothesize that sleep disturbance will be more severe in the CHR group in comparison to the healthy control (HC) group. Further, based on the same aforementioned studies, we hypothesize that within the CHR group, the severity of sleep disturbance will be positively associated with the severity of positive prodromal symptoms at baseline. With regard to the specificity of sleep disturbance-positive prodromal symptom associations, we hypothesize that sleep disturbance will be more strongly associated with paranoia/suspiciousness and perceptual abnormalities in this CHR sample. As the current study is cross-sectional in nature, we will assess the direct and indirect effects, rather than true meditational effects, which require longitudinal data. Based on previously discussed findings, we hypothesize that the indirect effect of sleep problems on positive prodromal symptoms through depressive symptoms will be significant in this analysis of a CHR sample. Finally, based on the ▇▇▇▇▇▇▇▇-▇▇▇▇▇ and colleagues (2017) finding that certain aspects of sleep disturbance predict worsening of psychotic symptoms over time, as well as theories that link sleep problems to worsening neuropsychiatric symptoms, we hypothesize that sleep disruption at the time of the baseline interview will predict later conversion to a psychotic disorder and/or will predict progression of the prodromal syndrome at a later time point. ▇▇▇ and colleagues (2017) previously tested this hypothesis on a sample of 194 CHR participants and found that sleep disturbance did not predict conversion to psychotic illness at 2.5-year follow-up. However, as described previously, conversion to psychotic illness occurs at a relatively low frequency, even in an enriched CHR sample, thus the ▇▇▇ and colleagues (2017) sample size of 194 may not have afforded adequate p...
View Source
Current Study. Aims and hypothesis Hypothesis 1 therefore stated that both interventions would reduce depressive symptoms, with mindfulness showing greater reduction. A second aim of the study was to explore the relationship between treatment- related changes in depressive symptoms and changes in cognitive functioning during the active treatment and follow-up stages. This aim was exploratory - to examine which factors contributed to changes in depressive symptoms, independently of intervention received. As part of these analyses, we conducted an exploratory mediation analysis in order to investigate whether changes in rumination mediated the effects of the treatments on depression. This was based on the assumption that mindfulness might exert stronger effects on symptoms due to its increased capacity to reduce rumination.
View Source

Related to Current Study

  • Feasibility Study Buyer is granted the right to conduct engineering and/or market and economic feasibility studies of the Property and a physical inspection of the Property, including studies or inspections to determine the existence of any environmental hazards or conditions (collectively, the “Feasibility Study”) during the period (the “Feasibility Period”) commencing on the Effective Date and ending at 5:00 p.m., Central Time, on the June 3, 2010. With Seller’s permission, after Seller has received advance notice sufficient to permit it to schedule in an orderly manner Buyer’s examination of the Property and to provide at least 24-hours’ advance written notice to any affected tenants, Buyer or its designated agents may enter upon the Property during normal business hours for purposes of analysis or other tests and inspections which may be deemed necessary by Buyer for the Feasibility Study. Buyer or its designated representative must be accompanied by a designated representative of Seller or have received Seller’s written permission prior to entering upon the Property in connection with Buyer’s Feasibility Study; provided, however, Buyer may not enter into any space leased by any tenant without being accompanied by a designated representative of Seller. Seller agrees to make its representative reasonably available during normal business hours. Buyer will not alter the physical condition of the Property or conduct invasive testing without notifying Seller of its requested tests, and obtaining the written consent of Seller to any physical alteration of the Property or invasive testing. Buyer will utilize commercially reasonable diligence to conduct or cause to be conducted all inspections and tests in a manner and at times which will not unreasonably interfere with any tenant’s use and occupancy of the Property. If Buyer determines, in its sole judgment, that the Property is not suitable for any reason for Buyer’s intended use or purpose, or is not in satisfactory condition, then Buyer may terminate this Contract by written notice to Seller prior to expiration of the Feasibility Period, in which case the ▇▇▇▇▇▇▇ Money (other than the Option Money) will be returned to Buyer, and neither party shall have any further right or obligation hereunder other than as set forth herein with respect to rights or obligations which survive termination. If this Contract is not terminated pursuant to this Section 5(a), then after expiration of the Feasibility Period, after Seller has received advance notice sufficient to permit it to schedule in an orderly manner Buyer’s examination of the Property and to provide at least 24-hours’ advance written notice to any affected tenants, Buyer or its designated agents may enter upon the Property during normal business hours. Buyer or its designated representative must be accompanied by a designated representative of Seller or have received Seller’s written permission prior to entering upon the Property; provided, however, Buyer may not enter into any space leased by any tenant without being accompanied by a designated representative of Seller. If this Contract is not timely terminated pursuant to this Section 5(a), Buyer’s right to terminate this Contract pursuant to this Section 5(a) and any and all objections with respect to the Feasibility Study will be deemed to have been waived by Buyer for all purposes.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Independent Study A sabbatical leave may be granted for a plan of independent study, research, writing, and/or travel equivalent in time and rigor to a sabbatical for formal study. A detailed, specific plan must be submitted by the applicant and approved by the Salary and Leaves Committee as likely to improve the applicant’s teaching effectiveness, strengthen the College’s academic program, or otherwise bring a clear benefit to students. In addition, sabbaticals for independent study must generate tangible products of use to students.